Gilead disputes report of anti-viral drug remdesivir failing Covid-19 trial

It comes days after another report of rapid recovery in fever and respiratory symptoms in some patients with Covid-19 who were treated with remdesivir at the University of Chicago Medicine hospital

A closely-watched Gilead Sciences Inc experimental antiviral drug failed to help patients with severe Covid-19 in a clinical trial conducted in China, but the drugmaker said the findings were inconclusive because the study was terminated early.

Gilead shares closed down 4.3% after the data was inadvertently released and first reported by the Financial Times. It comes days after another report detailed rapid recovery in fever and respiratory symptoms in some patients with Covid-19 - the sometimes deadly respiratory illness caused by the coronavirus - who were treated with remdesivir at the University of Chicago Medicine hospital.
 

Interest in Gilead's remdesivir